| # | % | |||||
|---|---|---|---|---|---|---|
| 101 | INOTEK PHARMACEUTICALS CORP | 7,000,000 | 9,547,000 | 0.11% | PRN | |
| 102 | AFFIMED N V | 3,375,000 | 9,383,000 | 0.11% | ||
| 103 | Nabriva Therapeutics AG | 1,315,000 | 9,271,000 | 0.11% | ||
| 104 | AEGLEA BIOTHERAPEUTICS INC COM | 1,360,224 | 8,719,000 | 0.10% | ||
| 105 | CELLECTIS S A | 350,000 | 8,428,000 | 0.10% | ||
| 106 | PORTOLA PHARMACEUTICALS INC | 370,900 | 8,423,000 | 0.10% | ||
| 107 | INCYTE CORP | 4,250,000 | 8,267,000 | 0.09% | PRN | |
| 108 | SIENTRA INC | 917,500 | 8,248,000 | 0.09% | ||
| 109 | NUVASIVE INC COM | 123,500 | 8,233,000 | 0.09% | ||
| 110 | XENON PHARMACEUTICALS INC | 1,000,000 | 8,100,000 | 0.09% | ||
| 111 | INCYTE CORP | 4,250,000 | 8,090,000 | 0.09% | PRN | |
| 112 | MINERVA NEUROSCIENCES INC COM | 556,200 | 7,851,000 | 0.09% | ||
| 113 | Redhill Biopharma Ltd | 564,900 | 7,846,000 | 0.09% | ||
| 114 | FLUIDIGM CORP DEL | 10,000,000 | 6,213,000 | 0.07% | PRN | |
| 115 | BRISTOL MYERS SQUIBB CO | 100,000 | 5,392,000 | 0.06% | Call | |
| 116 | ADAPTIMMUNE THERAPEUTICS PLC | 724,184 | 5,105,000 | 0.06% | ||
| 117 | INFINITY PHARMACEUTICALS INC COM | 3,250,300 | 5,070,000 | 0.06% | ||
| 118 | GW PHARMACEUTICALS PLC | 36,200 | 4,805,000 | 0.05% | ||
| 119 | VALEANT PHARMACEUTICALS INTL | 194,900 | 4,785,000 | 0.05% | ||
| 120 | INVITAE CORP | 456,666 | 4,000,000 | 0.05% | ||
| 121 | SANGAMO BIOSCIENCES INCORPORATED | 831,500 | 3,850,000 | 0.04% | ||
| 122 | UNIQURE NV | 489,000 | 3,741,000 | 0.04% | ||
| 123 | PERNIX THERAPEUTICS HOLDINGS INC | 12,000,000 | 3,514,000 | 0.04% | PRN | |
| 124 | AMEDISYS INC COM | 71,500 | 3,392,000 | 0.04% | ||
| 125 | ROKA BIOSCIENCE INC | 3,220,429 | 2,238,000 | 0.03% | ||
| 126 | Cogentix Medical Inc | 878,145 | 1,598,000 | 0.02% | ||
| 127 | OREXIGEN THERAPEUTICS INC | 5,210,000 | 1,441,000 | 0.02% | PRN | |
| 128 | INTRA CELLULAR THERAPIES INC COM | 90,000 | 1,373,000 | 0.02% | Call | |
| 129 | BIOLINERX LTD | 1,038,600 | 1,194,000 | 0.01% | ||
| 130 | AMARIN CORP PLC | 350,000 | 1,117,000 | 0.01% | ||
| 131 | MARINUS PHARMACEUTICALS INC | 567,600 | 1,033,000 | 0.01% | ||
| 132 | QLT INC | 500,000 | 1,030,000 | 0.01% | ||
| 133 | MEDIGUS LTD | 600,000 | 756,000 | 0.01% | ||
| 134 | PERNIX THERAPEUTICS HLDGS IN | 1,073,000 | 668,000 | 0.01% | ||
| 135 | BioMarin Pharmaceutical Inc | 500,000 | 624,000 | 0.01% | PRN | |
| 136 | BIOMARIN PHARMACEUTICAL INC | 500,000 | 600,000 | 0.01% | PRN | |
| 137 | XTANT MED HLDGS INC | 475,439 | 537,000 | 0.01% | ||
| 138 | Nivalis Therapeutics Inc | 59,000 | 480,000 | 0.01% | ||
| 139 | ALIMERA SCIENCES INC | 250,000 | 373,000 | 0.00% | ||
| 140 | ARALEZ PHARMACEUTICALS INC | 68,143 | 330,000 | 0.00% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001172661-16-004318, filed 2016.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
